HIV感染女性中现行HPV疫苗覆盖的肛门与宫颈高危HPV型别的患病率与发病率:SUN研究
SUN研究纳入167名美国HIV感染女性,2004-2006年入组,每年采集肛门和宫颈标本检测37种HPV型别。基线126名女性中,肛门和宫颈9价疫苗高危型HPV患病率分别为67%和51%,非9价高危型分别为54%和29%;两组发病率相似,9价型别清除率较低。作者认为这些发现支持在HIV感染女性中使用9价疫苗。
要点
- 肛门高危HPV患病率(90%)高于宫颈(83%),9价型别分别为67%和51%。
- 9价与非9价高危HPV发病率相似,肛门为10.4 vs 9.5/100人年,宫颈为8.5 vs 8.3/100人年。
- 9价高危HPV清除率在肛门和宫颈分别为42%和61%,非9价为46%和59%。
核心结论
- 肛门高危HPV患病率高于宫颈且清除率较低,但两者发病率相似。
- 尽管非9价高危HPV患病率可观,9价高危HPV型别总体上更常见。
- 作者认为这些发现支持在HIV感染女性中使用9价疫苗。
研究设计与样本
- SUN研究于2004-2006年在美国纳入167名HIV感染女性。
- 每年采集肛门和宫颈标本进行细胞学检查及37种HPV型别检测。
- 37种型别中14种高危型包括9价疫苗覆盖的16、18、31、33、45、52、58及非9价的35、39、51、56、59、66、68。
- 基线分析纳入126名女性。
主要发现
- 基线特征:中位年龄38岁;57%为非西班牙裔黑人;67% HIV RNA<400拷贝/mL;90% CD4计数≥200细胞/mm3。
- 肛门和宫颈HPV总患病率分别为90%和83%。
- 9价高危HPV患病率在肛门为67%、宫颈为51%;非9价高危HPV分别为54%和29%。
- 9价与非9价高危HPV发病率/100人年:肛门10.4 vs 9.5,宫颈8.5 vs 8.3。
- 9价高危HPV清除率在肛门和宫颈分别为42%和61%;非9价为46%和59%。
临床怎么用
- 作者认为这些发现支持在HIV感染女性中使用9价疫苗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nonavalent (9v) human papilloma virus vaccine targets high-risk human papillomavirus (HR-HPV) types 16, 18, 31, 33, 45, 52, 58, and low-risk 6, 11. We examined prevalence, incidence, and clearance of anal and cervical HR-HPV in HIV-infected women. METHODS: The SUN Study enrolled 167 US women in 2004-2006. Anal and cervical specimens were collected annually for cytology and identification of 37 HPV types: 14 HR included: 9v 16, 18, 31, 33, 45, 52, 58; non-9v 35, 39, 51, 56, 59, 66, 68. RESULTS: Baseline characteristics of 126 women included: median age 38 years; 57% non-Hispanic black; 67% HIV RNA < 400 copies/mL; 90% CD4 counts ≥200 cells/mm3. HPV prevalence at anus and cervix was 90% and 83%; for 9v HR-HPV types, 67% and 51%; non-9v HR-HPV, 54% and 29%, respectively. The 9v and non-9v HR-HPV incidence rates/100 person-years were similar (10.4 vs 9.5; 8.5 vs 8.3, respectively); 9v clearance rates were 42% and 61%; non-9v 46% and 59%, in anus and cervix, respectively. CONCLUSIONS: Anal HR-HPV prevalence was higher than cervical, with lower clearance; incidence was similar. Although prevalence of non-9v HR-HPV was substantial, 9v HR-HPV types were generally more prevalent. These findings support use of nonavalent vaccine in HIV-infected women.
引用
- Kojic EM, Conley L, Bush T, et al. Prevalence and Incidence of Anal and Cervical High-Risk Human Papillomavirus (HPV) Types Covered by Current HPV Vaccines Among HIV-Infected Women in the SUN Study. J Infect Dis. 2018. PMID: 29452366. doi:10.1093/infdis/jiy087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。